Spectral Medical (Edtxf) (TSE:EDT) has released an update.
Spectral Medical Inc. has announced a C$8.5 million financing deal through the sale of 9% convertible notes due in 2028, with an over-allotment option of 15% available to the underwriter. The proceeds are primarily intended for the Phase III trial of their sepsis treatment, PMX, and general corporate purposes, with the offering’s close expected around May 23, 2024. This funding move comes as the company seeks FDA approval for PMX, which has been used effectively in Japan and Europe and recently received Breakthrough Device Designation from the U.S. FDA.
For further insights into TSE:EDT stock, check out TipRanks’ Stock Analysis page.
